- United States
- /
- Healthcare Services
- /
- NasdaqCM:NEO
NeoGenomics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
NeoGenomics (NASDAQ:NEO) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$164.5m (up 12% from 2Q 2023).
- Net loss: US$18.6m (loss narrowed by 23% from 2Q 2023).
- US$0.15 loss per share (improved from US$0.19 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
NeoGenomics Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 1.5%. Earnings per share (EPS) missed analyst estimates by 9.1%.
Looking ahead, revenue is forecast to grow 9.9% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in the US.
Performance of the American Healthcare industry.
The company's shares are up 16% from a week ago.
Risk Analysis
Before you take the next step you should know about the 1 warning sign for NeoGenomics that we have uncovered.
Valuation is complex, but we're here to simplify it.
Discover if NeoGenomics might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About NasdaqCM:NEO
NeoGenomics
Operates a network of cancer-focused testing laboratories in the United States and the United Kingdom.
Adequate balance sheet and slightly overvalued.